文献速递前列腺癌

基于PROBASE试验数据的风险调整前列腺癌筛查:定义低风险组

Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
PubMed 文献 · Eur Urol · 2024-05-15

PROBASE试验在德国开展基于人群的风险调整前列腺癌筛查,对45岁男性检测基线PSA。基线PSA<1.5 ng/ml者5年内前列腺癌风险极低,而PSA 1.5-3.0 ng/ml者风险较高。

要点

  • 45岁男性基线PSA<1.5 ng/ml者5年内前列腺癌风险极低
  • 基线PSA 1.5-3.0 ng/ml者后续筛查中前列腺癌风险明显升高
  • 基线PSA<1.5 ng/ml的男性5年内无需重复PSA检测

核心结论

  • 45岁时基线PSA<1.5 ng/ml的男性未来5年前列腺癌风险极低。

研究设计与样本

  • 德国基于人群的风险调整前列腺癌筛查试验(PROBASE),从45岁开始检测PSA,共23301名男性接受首次PSA检测。

主要发现

  • 23301名45岁接受首次PSA检测的男性中,0.79% PSA≥3 ng/ml为筛查阳性。
  • 基线PSA<1.5 ng/ml的男性占89%,其中仅0.45%在5年后复测时PSA≥3 ng/ml。
  • 基线PSA 1.5-3 ng/ml的筛查阴性男性中,13%在随后4年内每两年检测时PSA超过3 ng/ml。
  • 后续筛查轮次中前列腺癌发病率随基线PSA水平升高而增加,从基线PSA<1.5 ng/ml者的0.13/1000人年升至PSA 1.5-3.0 ng/ml者的8.0/1000人年。

临床怎么用

  • 45岁男性基线PSA<1.5 ng/ml者5年内前列腺癌检出率极低,此期间无需重复PSA检测。

局限性

  • 随访时间目前仅5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr. OBJECTIVE: To identify men at age 45 yr with a low risk of PCa. DESIGN, SETTING, AND PARTICIPANTS: A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE). INTERVENTION: PSA measurements starting at the age of 45 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The incidence of PCa within 5 yr was assessed in men with screen-negative baseline PSA <1.5 ng/ml compared with those with PSA 1.5-≤3.0 ng/ml. RESULTS AND LIMITATIONS: Of 23301 men who received a first PSA test at age 45 yr, 0.79% had a screen-positive PSA value of ≥3 ng/ml. Among the 89% of men who had a screen-negative baseline PSA value of <1.5 ng/ml, only 0.45% received a positive PSA test ≥3 ng/ml upon retesting after 5 yr. By contrast, for those with a screen-negative baseline PSA value of 1.5-3 ng/ml, 13% surpassed 3 ng/ml upon biennial testing within the next 4 yr. The incidence of PCa in subsequent screening rounds increased with increasing baseline PSA levels, from 0.13 per 1000 person-years for men with initial PSA level of <1.5 ng/ml to 8.0 per 1000 person-years for those with PSA levels of 1.5-3.0 ng/ml. A limitation is a follow-up time of only 5 yr, so far. CONCLUSIONS: Men with baseline PSA <1.5 ng/ml at age 45 yr are at a very low risk of PCa over the next 5 yr. PATIENT SUMMARY: The PROBASE study showed that men with baseline prostate-specific antigen (PSA) <1.5 ng/ml at age 45 yr have a very low prostate cancer detection rate over 5 yr and do not need PSA retesting during this time.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Krilaviciute A, Kaaks R, Seibold P, et al. Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Eur Urol. 2024. PMID: 38749854. doi:10.1016/j.eururo.2024.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。